These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 16680149

  • 1. Eradication of established tumors in mice by a combination antibody-based therapy.
    Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ.
    Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
    [Abstract] [Full Text] [Related]

  • 2. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
    Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K.
    Cell Immunol; 2001 Dec 15; 214(2):194-200. PubMed ID: 12088418
    [Abstract] [Full Text] [Related]

  • 3. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
    Ishikawa E, Nakazawa M, Yoshinari M, Minami M.
    J Virol; 2005 Jun 15; 79(12):7658-63. PubMed ID: 15919918
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ.
    J Immunol; 2010 May 15; 184(10):5493-501. PubMed ID: 20400706
    [Abstract] [Full Text] [Related]

  • 5. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
    Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T.
    Nat Med; 2001 Aug 15; 7(8):954-60. PubMed ID: 11479629
    [Abstract] [Full Text] [Related]

  • 6. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E, Takeda K, Smyth MJ.
    Int J Biochem Cell Biol; 2007 Aug 15; 39(2):280-6. PubMed ID: 17097329
    [Abstract] [Full Text] [Related]

  • 7. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
    Herbeuval JP, Shearer GM.
    AIDS Rev; 2006 Aug 15; 8(1):3-8. PubMed ID: 16736946
    [Abstract] [Full Text] [Related]

  • 8. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
    Mori E, Thomas M, Motoki K, Kataika S.
    FEBS Lett; 2005 Oct 10; 579(24):5379-84. PubMed ID: 16199041
    [Abstract] [Full Text] [Related]

  • 9. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J, Hu P, Khawli LA, Epstein AL.
    Cancer Res; 2003 Dec 01; 63(23):8384-92. PubMed ID: 14679000
    [Abstract] [Full Text] [Related]

  • 10. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ.
    Proc Natl Acad Sci U S A; 2006 Jun 06; 103(23):8634-9. PubMed ID: 16731632
    [Abstract] [Full Text] [Related]

  • 11. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK.
    J Clin Oncol; 2005 Dec 20; 23(36):9394-407. PubMed ID: 16361639
    [Abstract] [Full Text] [Related]

  • 12. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
    Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C.
    Oncogene; 2006 Aug 24; 25(37):5145-54. PubMed ID: 16636678
    [Abstract] [Full Text] [Related]

  • 13. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
    Wilcox RA, Flies DB, Wang H, Tamada K, Johnson AJ, Pease LR, Rodriguez M, Guo Y, Chen L.
    Cancer Res; 2002 Aug 01; 62(15):4413-8. PubMed ID: 12154048
    [Abstract] [Full Text] [Related]

  • 14. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL, Griffith TS.
    Cancer Res; 2007 Dec 15; 67(24):11980-90. PubMed ID: 18089829
    [Abstract] [Full Text] [Related]

  • 15. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
    Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hämmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ.
    J Immunol; 2010 Jul 01; 185(1):532-41. PubMed ID: 20505139
    [Abstract] [Full Text] [Related]

  • 16. Characterization of monoclonal antibodies directed against trail or trail receptors.
    Vermot-Desroches C, Sergent E, Bonnin B, Wijdenes J.
    Cell Immunol; 2005 Jul 01; 236(1-2):86-91. PubMed ID: 16157319
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.
    Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135
    [Abstract] [Full Text] [Related]

  • 18. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
    Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, Tsokos M, Kontny HU, Mackall CL.
    Cancer Res; 2004 Nov 15; 64(22):8349-56. PubMed ID: 15548704
    [Abstract] [Full Text] [Related]

  • 19. Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production.
    Konur A, Schulz U, Eissner G, Andreesen R, Holler E.
    Br J Dermatol; 2005 Jun 15; 152(6):1134-42. PubMed ID: 15948973
    [Abstract] [Full Text] [Related]

  • 20. Targeting death-inducing receptors in cancer therapy.
    Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ.
    Oncogene; 2007 May 28; 26(25):3745-57. PubMed ID: 17530027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.